A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial

This article has no abstract
Epistemonikos ID: f82e60858c8d403b5220e03b6e3f82731e9a5709
First added on: Feb 04, 2025